OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ZJYL
Jin Medical International Ltd.
There isn't enough reported data to score ZJYL yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZJYL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Weak |
ZJYL's profitability is currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue and cash flow.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ZJYL in the historical PE scenario, which offers more potential upside but is not a forecast.
ZJYL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $2.19 | -43% |
| Fair | 18x | $3.67 | -5.1% |
| Current | 21x | $3.87 | — |
| Expensive | 161x | $32.23 | +733% |
Historical ranges are pointers, not guarantees.
ZJYL's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ZJYL Forward outlook
There aren't enough analyst estimates for ZJYL to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ZJYL Earnings Per Share
ZJYL and OSCR do not have enough comparable growth data to identify a winner.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ZJYL in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ZJYL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $8.9M | -9.7% |
| Q3 2025 | $10.8M | -17% |
| Q1 2025 | $9.9M | -6.4% |
| Q3 2024 | $12.9M | +35% |
| Q1 2024 | $10.6M | +3% |
| Q3 2023 | $9.6M | -1.6% |
| Q1 2023 | $10.3M | +8.3% |
| Q3 2022 | $9.7M | -14% |
ZJYL's revenue is growing: $9M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -7.2% | -19 points |
| Q3 2025 | 9.8% | -1.6 points |
| Q1 2025 | -4.6% | -22 points |
| Q3 2024 | 19% | +7.1 points |
| Q1 2024 | 12% | +0.9 points |
| Q3 2023 | 11% | +4.5 points |
| Q1 2023 | 17% | -2.3 points |
| Q3 2022 | 11% | -1.6 points |
ZJYL's operating margin was −7.2% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
ZJYL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.7M | -633% |
| Q3 2025 | -$4.2M | -$2.9M |
| Q1 2025 | $510.9K | +$544.6K |
| Q3 2024 | -$1.3M | -607% |
| Q1 2024 | -$33.7K | -101% |
| Q3 2023 | $260K | -84% |
| Q1 2023 | $2.7M | +$2.8M |
| Q3 2022 | $1.6M | -19% |
ZJYL's free cash flow was −$8M over the past year, against $5M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ZJYL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2 shares |
| 1 year | +0.1% | +7.3K shares |
| 3 years | -61% | -12.2M shares |
ZJYL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2022 | — |
| Q1 2022 | — |
| Q3 2021 | — |
| Q1 2021 | — |
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ZJYL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 13.4x | High |
| Q1 2025 | 2.1x | Moderate |
| Q3 2024 | 0.8x | Very low |
| Q1 2024 | 0.3x | Very low |
ZJYL's net debt is about 13 years of its operating earnings (EBITDA).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ZJYL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 61.8 | Neutral |
ZJYL's weekly RSI is 66 (neutral) and its Stochastic is 62 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ZJYL on valuation relative to its sector.
ZJYL PE vs Healthcare Sector
| Metric | ZJYL | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 20% below |
| PE % | 55 | 39 | 16 pts above |
ZJYL is trading at 21x earnings, a 20% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has stronger trend alignment. OSCR is above 5 of 5 weekly averages versus ZJYL above 3 of 4.
ZJYL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.45 | 58% above |
| 20 week MA | $2.32 | 67% above |
| 50 week MA | $2.64 | 47% above |
| 100 week MA | $8.05 | 52% below |
ZJYL has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 52% below its 100-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ZJYL on returns for 2026, with the stronger performance.
ZJYL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $7.45 | $248.1 | +3230% |
| 2024 | $248.1 | $21.0 | -92% |
| 2025 | $21.0 | $4.46 | -79% |
| 2026 YTD | $4.46 | $3.87 | -13% |
ZJYL's yearly returns have swung widely, from +3230% in 2023 to −92% in 2024. It's down 13% so far in 2026.